Viekirax

RSS

ombitasvir / paritaprevir / ritonavir

Authorised
This medicine is authorised for use in the European Union.

Overview

Viekirax is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of the liver caused by the hepatitis C virus.

It contains 3 active substances: ombitasvir, paritaprevir and ritonavir.

This EPAR was last updated on 12/08/2022

Authorisation details

Product details
Name
Viekirax
Agency product number
EMEA/H/C/003839
Active substance
  • Ombitasvir
  • paritaprevir
  • ritonavir
International non-proprietary name (INN) or common name
  • ombitasvir
  • paritaprevir
  • ritonavir
Therapeutic area (MeSH)
Hepatitis C, Chronic
Anatomical therapeutic chemical (ATC) code
J05AP53
Publication details
Marketing-authorisation holder
AbbVie Deutschland GmbH Co. KG
Revision
27
Date of issue of marketing authorisation valid throughout the European Union
14/01/2015
Contact address

Knollstrasse
67061 Ludwigshafen
Germany

Product information

12/08/2022 Viekirax - EMEA/H/C/003839 - N/0067

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

For hepatitis C virus (HCV) genotype specific activity.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating